扫一扫,慧博手机终端下载!
位置: 首 页 > 定期财报 > 三季度报告

华东医药定期财报:华东医药:2019年第三季度报告全文(英文版)

股票名称:华东医药 股票代码:000963
研报类型:(PDF) 研报栏目:定期财报
研报大小:787K 分享时间:2019-11-08 20:46:02
如需数据加工服务,数据接口服务, 请联系客服电话 : 400-806-1866

【财报摘要】

2019ThirdQuarterlyReportofHuadongMedicineCo.,Ltd.1HuadongMedicineCo.,Ltd.2019ThirdQuarterlyReportOctober20192019ThirdQuarterlyReportofHuadongMedicineCo.,Ltd.2SectionIImportantNotesTheBoardofDirectors,BoardofSupervisors,directors,supervisorsandseniormanagementofHuadongMedicineCo.,Ltd.(the“Company”)herebyguaranteethattheinformationpresentedinthisreportisauthentic,accurateandcompleteandfreeofanyfalserecords,misleadingstatementsormaterialomissions,andwillundertakeindividualandjointlegalliabilities.Alldirectorshaveattendedtheboardmeetingtoreviewthisquarterlyreport.LyuLiang,theCompany’slegalrepresentativeandtheofficerinchargeofaccounting,andMaHonglan,headofaccountingdepartment(accountingsupervisor)herebydeclareandwarrantthatthefinancialstatementsinthisreportareauthentic,accurateandcomplete.Accordingto“StockListingRulesoftheShenzhenStockExchange(2018Revision)”,iflistedcompanieshavebothChineseandotherlanguageversionsofpublicnotice,theyshouldensurethecontentofbothversionsarethesame.Inthecaseofdiscrepancy,theoriginalversioninChineseshallprevail.2019ThirdQuarterlyReportofHuadongMedicineCo.,Ltd.3SectionIICompanyProfileI.KeyaccountingdataandfinancialindicatorsWhethertheCompanyneedstoperformaretroactiveadjustmentorrestatementofthepreviousaccountingdata√Yes□NoReasonsforretroactiveadjustmentorrestatementOtherreasonAtSeptember30,2019AtDecember31,2018ChangebetweenDecember31,2018andSeptember30,2019(%)BeforeadjustmentAfteradjustmentAfteradjustmentTotalassets(yuan)22,510,034,334.4819,217,357,282.3319,217,357,282.3317.13%NetassetsattributabletoshareholdersoftheCompany(yuan)11,661,608,297.709,938,148,996.539,938,148,996.5317.34%2019Q3YoYChangebetween2018Q3and2019Q3(%)2019Q1-Q3YoYChangebetween2018Q1-Q3and2019Q1-Q3(%)Operatingrevenue(yuan)9,379,217,601.8919.03%27,627,885,218.8719.06%NetprofitsattributabletoshareholdersoftheCompany(yuan)616,830,635.7719.61%2,213,114,054.0822.33%NetprofitsattributabletoshareholdersoftheCompanyafterdeductingnon-recurringprofitorloss(yuan)605,703,004.5217.68%2,079,980,188.5516.59%Netcashflowsfromoperatingactivities(yuan)--909,038,245.94-35.59%Basicearningspershare(yuanpershare)0.352519.61%1.264822.33%Dilutedearningspershare(yuanpershare)0.352519.61%1.264822.33%WeightedaverageReturnonEquity(ROE)5.44%-0.14%20.14%0.18%Note:AstheCompanyincreasedsharecapitalbyconvertingcapitalreserveinJune2019,earningspershareofprecedingperiodwasadjustedbasedontheincreasedcapitalunderrelevantaccountingstandards……

推荐给朋友:
我要上传
用户已上传 11,410,411 份投研文档
云文档管理
设为首页 加入收藏 联系我们 反馈建议 招贤纳士 合作加盟 免责声明
客服电话:400-806-1866     客服QQ:1223022    客服Email:hbzixun@126.com
Copyright@2002-2024 Hibor.net 备案序号:京ICP备14012269号-5  京公网安备:11011202003262
本网站用于投资学习与研究用途,如果您的文章和报告不愿意在我们平台展示,请联系我们,谢谢!

不良信息举报电话:400-806-1866 举报邮箱:hbzixun@126.com